Drug delivery and nanoparticles: Applications and hazards

International Journal of Nanomedicine

Volumn 3, Issue 2, 2008, Pages 133-149

  De Jong, Wim H ^a   Borm, Paul J A ^b,c  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^b ZUYD UNIVERSITY OF APPLIED SCIENCES   (Netherlands)

^c MagnaMedics GmbH   (Germany)

Author keywords

Cancer theraphy; Drug delivery; Nanoparticles; Pharmaceuticals; Toxicology

Indexed keywords

CARBON NANOTUBE; CHITOSAN; DENDRIMER; DEXTRAN; DODECYLAMINE; DOXORUBICIN; FULLERENE DERIVATIVE; GLYCOPROTEIN P; GOLD; MACROGOL; N ACETYLGLUCOSAMINE; NANOCARRIER; NANOMATERIAL; NANOSHELL; OLEATE SODIUM; PACLITAXEL; PHTHALOCYANINE ZINC; POVIDONE; PULLULAN; QUANTUM DOT; SIALIC ACID; SILICON DIOXIDE; WHEAT GERM AGGLUTININ;

AREA UNDER THE CURVE; BIOAVAILABILITY; BIODEGRADATION; BLOOD BRAIN BARRIER; BRAIN; CYTOSOL; CYTOTOXICITY; DRUG BINDING; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG PENETRATION; DRUG RELEASE; DRUG TARGETING; DRUG UPTAKE; ENDOCYTOSIS; HAZARD ASSESSMENT; HUMAN; LIVER; MATERIAL COATING; NANOENCAPSULATION; NANOPHARMACEUTICS; NANOTOXICOLOGY; NEOPLASM; NONHUMAN; PARTICLE SIZE; PARTICULATE MATTER; PHYSICAL CHEMISTRY; REVIEW;

DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; NANOMEDICINE; NANOPARTICLES;

EID: 61349139614     PISSN: 11769114     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (155)

1. Albrecht C, Knaapen AM, Becker et al. 2005. The crucial role of particle surface reactivity in respirable quartz induced reactive oxygen/nitrogen species formation and APE/Ref-1 induction in rat lung. Respir Res, 6:129.
2. Åkerman ME, Chan WCW, Laakkonen P, et al. 2002. Nonocrystal targeting in vivo. PNAS, 99:12617-21.
3. Alyautdin RN, Petrov VE, Langer K, et al. 1997. Delivery of loperamide across the blood-brain barrier with polysorbate 80-coated polybutylcyanoacrylate nanoparticles. J Pharm Res. 14:325-8.
4. Ballou B, Lagerholm BC, Ernst LA, et al. 2004. Non-invasive imaging of quantum dots in mice. Bioconjug Chem, 15:79-86.
5. Baran ET, Özer N, Hasirci V. 2002. In vivo half life of nanoencapsulated L-asparaginase. J Mat Sc: Mat in Med, 13:1113-21.
6. Bazile D, Prud'Homme C, Bassoullet M-T, et al. 1995. Stealth PEG-PLA nanoparticles avoid uptake by the mononuclear phagocytes system. J Pharm Sci, 84:493-8.
7. Benardi RJ, Lowery AR, Thompson PA, et al. 2007. Immunoshells for targeted photothermal ablation in medulloblastoma and glioma: an in vitro evaluation using human cell lines. J Neurooncol, Sep 6 Epub ahead of print.
8. Borm PJ. 2002. Particle toxicology: from coal mining to nanotechnology. Inhal Toxicol, 14:311-24.
9. Borm PJ, Kreyling W. 2004. Toxicological hazards of inhaled nanoparticles - potential implications for drug delivery. J Nanosc Nanotechnol, 4:521-31.
10. Borm PJ, Muller-Schulte D. 2006. Nanoparticles in drug delivery and environmental exposure: same size, same risks? Nanomedicine, 1:235-49
11. Borm PJA, Robbins D, Haubold S, et al. 2006. The potential risks of nanomaterials: a review carried out for ECETOC. Part Fiber Toxicol, 3:11.
12. Bourges JL, Gautier SE, Delie F, et al. 2003. Ocular drug delivery targeting the retina and retinal pigment epithelium using polylactide nanoparticles. Invest Ophthalmol Vis Sci, 44:3562-9.
13. Brook RD, Franklin B, Cascio W, et al. 2004. Air pollution and vascular disease. A statement for healthcare professionals from the expert panel on population and prevention science of the American Heart Association. Circulation, 109:2655-71.
14. Buxton DB, Lee SC, Wickline SA, et al. 2003. Recommendations of the National Heart, Lung, and Blood Institute Nanotechnology Working Group. Circulation, 108:2737-42.
15. Calderon-Garciduenas L, Reed W, Maronpot RR, et al. 2004. Brain inflammation and Alzheimer's-like pathology in individuals exposed to severe air pollution. Toxicol Pathol, 32:650-8.
16. Campbell A, Oldham M, Becaria A, et al. 2005. Particulate matter in polluted air may increase biomarkers of inflammation in mouse brain. Neurotoxicology, 26:133-40.
17. Campen MJ, McDonald JD, Gigliotti AP, et al. 2003. Cardiovascular effects of inhaled diesel exhaust in spontaneously hypertensive rats. Cardiovasc Toxicol, 3:353-61.
18. Carty CL, Gehring U, Cyrys J, et al. 2003. Seasonal variability of endotoxin in ambient fine particulate matter. J Environm Monit, 5:953-8.
19. Cascone MG, Lazzeri L, Carmignani C, et al. 2002. Gelatin nanoparticles produced by a simple W/O emulsion as delivery system for methotrexate. J Mat Sc: Mat in Med, 13:523-6.
20. Chang JS, Chang KLB, Hwang DF, et al. 2007. In vitro cytotoxicity of silica nanoparticles at high concentrations strongly depends on the metabolic activity type of the cell line. Environ Sci Technol, 41:2064-8.
21. Chen LC, Nadziejko C. 2005. Effects of subchronic exposures to concentrated ambient particles (CAPs) in mice. V. CAPs exacerbate aortic plaque development in hyperlipidemic mice. Inhal Toxicol, 17:217-24.
22. Cho SJ, Maysinger D, Jain M, et al. 2007. Long term exposure to CdTe quantum dots causes functional impairment in living cells. Langmuir, 23:1974-80.
23. Choi AO, Cho SJ, Desbarats J, et al. 2007. Quantum dot-induced cell death involves Fas upregulation and lipid peroxidation in human neuroblastoma cells. J Nanobiotechnology, 12:1.
24. Connor EE, Mwamuka J, Gole A, et al. 2005. Gold nanoparticles are taken up by human cells but do not cause acute cytotoxicity. Small, 1:325-7.
25. Costigan S. 2006. The toxicology of nanoparticles used in health care products. Available at the website of the Medicines and Healthcare products Regulatory Agency, Department of Health, UK. Accessed 20 November 2006. URL: http://www.mhra.gov.uk/home/idcplg?IdcService= SS_GET_PAGE&nodeId=996
26. Crommelin DJ, Storm G. 2003. Liposomes: from the bench to the bed. J Liposome Res, 13:33-6.
27. Damascelli B, Patelli GL, Lanocita R, et al. 2003. A novel intraarterial chemotherapy using paclitaxel in albumin nanoparticles to treat advanced squamous cell carcinoma of the tongue: preliminary findings. Am J Roentgenol, 181:253-603.
28. De Jong WH, Geertsma RE, Roszek B. 2005. Nanotechnology in medical applications. Possible risks for human health. Report 265001002/2005, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Nethrlands.
29. Demoy M, Gibaud S, Andreux JP, et al. 1997. Splenic trapping of nanoparticles: complementary approaches for in situ studies. Pharm Res, 14:463-8.
30. Derfus AM, Chan WCW, Bhatia SN. 2004. Probing the cytotoxicity of semiconductor quantum dots. Nano Letters, 4:11-18.
31. Dockery DW, Pope CA, Xu X, et al. 1993. An association between air pollution and mortality in six U.S. cities. N Engl J Med, 329:1753-9.
32. Donaldson K, Aitken R, Tran L, et al. 2006. Carbon nanotubes: a review of their properties in relation to pulmonary toxicology and workplace safety. Toxicol Sci, 92:5-22.
33. Donaldson K, Brown D, Clouter A, et al. 2002. The pulmonary toxicology of ultrafine particles. J Aerosol Med, 15:213-20.
34. Donaldson K, Stone V. 2003. Current hypotheses on the mechanism of toxicity of ultrafine particles. Ann Ist Super Sanità, 39:405-10.
35. Donaldson K, Stone V, Clouter A, et al. 2001. Ultrafine particles. Occup Environ Med, 58:211-16.
36. Donaldson K, Stone V, Tran CL, et al. 2004. Nanotoxicology. Occup Environ Med, 61:727-28.
37. Donaldson K, Tran L, Jimenez LA, et al. 2005. Combustion-derived nanoparticles: a review of their toxicology following inhalation exposure. Part Fibre Toxicol, 2:10.
38. Dreher KL. 2004. Toxicological highlight. Health and environmental impact of nanotechnology: Toxicological assessment of manufactured nanoparticles. Toxicol Sc, 77:3-5.
39. Duncan R. 2003. The dawning era of polymer therapeutics. Nat Rev Drug Disc, 2:347-60.
40. Duncan R, Izzo L. 2005. Dendrimer biocompatibility and toxicity. Adv Drug Deliv Rev, 57:2215-37.
41. Dyer M, Hinchcliffe M, Watts P, et al. 2002. Nasal delivery of insulin using novel chitosan based formulations: a comparative study in two animal models between simple chitosan formulations and chitosan nanoparticles. Pharm Res, 19:998-1008.
42. Edetsberger M, Gaubitzer E, Valic E, et al. 2005. Detection of nanometersized particles in living cells using modern fluorescence fluctuation methods. Biochem Biophys Res Commun, 332:109-16.
43. Elder A, Gelein R, Silva V, et al. 2006. Translocation of inhaled ultrafine manganese oxide particles to the central nervous system. Environ Health Perspect, 114:1172-8.
44. European Technology Platform on Nanomedicine. 2005. Vision paper and basis for a strategic research agenda for nanomedicine. European Commission Luxembourg, Office for Official Publications of the European Commission, ISBN 92-894-9599-5.
45. European Science Foundation 2005. Policy Briefing (ESF), ESF Scientific Forward Look on Nanomedicine IREG Strasbourg, France, ISBN 2-912049-520, 2005.
46. Fang C, Shi B, Pei YY, et al. 2006. In vivo tumor targeting of tumor necrosis factor-alpha-loaded stealth nanoparticles: Effect of MePEG molecular weight and particle size. Eur J Pharm Sci, 27:27-36.
47. Fattal E, Vauthier C, Aynie I, et al. 1998. Biodegradable polyalkylcyanoacrylate nanoparticles for the delivery of oligonucleotides. J Control Release, 53:137-43.
48. Fernández-Urrusuno R, Fattal E, Porquet D, et al. 1995. Evaluation of liver toxicological effects induced by polyalkylcyanoacrylate nanoparticles. Toxicol Appl Pharmacol, 130:272-9.
49. Fernández-Urrusuno R, Fattal E, Féger J, et al. 1997. Evaluation of hepatic antioxidant systems after intravenous administration of polymeric nanoparticles. Biomaterials, 18:511-17.
50. Ferrari M. 2005. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer, 5:161-71.
51. Fishbein I, Chorny M, Banai S, et al. 2001. Formulation and delivery mode affect disposition and activity of tyrphostin-loaded nanoparticles in the rat carotid model. Arterioscler Thromb Vasc Biol, 21:1434-9.
52. Gao X, Tao W, Lu W, et al. 2006. Lectin-conjugated PEG-PLA nanoparticles: preparation and brain delivery after intranasal administration. Biomaterials, 27:3482-90.
53. Gibaud S, Demoy M, Andreux JP, et al. 1996. Cells involved in the capture of nanoparticles in hematopoietic organs. J Pharm Sci, 85:944-50.
54. Girardin F. 2006. Membrane transporter proteins: a challenge for CNS drug development. Dialogues Cliin Neurosci, 8:311-21.
55. Gomes AJ, Lunardi LO, Marchetti JM, et al. 2006. Indocyanine green nanoparticles useful for photomedicine. Photomed Laser Surg, 24:514-21.
56. Granum B, Lovik M. 2002. The effect of particles on allergic immune responses. Toxicol Sci, 65:7-17.
57. Gupta AK, Curtis ASG. 2004. Surface modified supermagnetic nanoparticles for drug delivery: interaction studies with human firbroblasts in culture. J Mater Sci: Mat in Med. 15:493-6.
58. Gupta M, Gupta AK. 2004. In vitro cytotoxicity studies of hydrogel pullulan nanoparticles prepared by AOT/N-hexane micellar system. J Pharm Pharmaceut Sci, 7:38-46.
59. Gupta AK, Gupta M. 2005. Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials, 26:3995-4021.
60. Hainfeld JF, Slatkin DN, Smilowitz HM. 2004. The use of gold nanoparticles to enhance radiotherapy in mice. Phys Med Biol, 49:309-15.
61. Hardman R. 2006. A toxicological review of quantum dots: toxicity depends on physicochemical and environmental factors. Environ Health Perspect, 114:165-72.
62. Health Council of the Netherlands. Health significance of nanotechnologies. The Hague: Health Council of the Netherlands, 2006; publication no. 2006/06E; http://www.healthcouncil.n1.
63. Hett A. 2004. Nanotechnology. Small matter, many unknowns. Risk perception. Swiss Re, Zurich, Switzerland.
64. Hirsch LR, Stafford RJ, Bankson JA, et al. 2003. Nanoshell-mediated near-infrared thermal therapy of tumors under magnetic resonance guidance. Proc Natl Acad Sci USA, 100:13549-54.
65. Hoshino A, Fujioka K, Oku T, et al. 2004. Physicochemical properties and cellular toxicity of nanocrystal quantum dots depend on their surface modification. Nano Lett, 4:2163-9.
66. Hoshino A, Manabe N, Fujioka K, et al. 2007. Use of fluorescent quantum dot bioconjugates for cellular imaging of immune cells, cell organelle labeling, and nanomedicine: surface modification regulates biological function, including cytotoxicity. J Artif Organs, 10:149-57.
67. Huang M, Khor E, Lim L-Y. 2004. Uptake and cytotoxicity of chitosan molecules and nanoparticles: effects of molecular weight and degree of deacetylation. Pharm Res, 21:344-53.
68. JECFA (Joint FAO/WHO Expert Committee on Food additives) Summary of Evaluations Performed by the Joint FAO/WHO Expert Committee on Food Additives, INS 175. 2001. http://jecfa.ilsi.org/evaluation. cfm?chemical=GOLD%20(METALLIC)&keyword=GOLD
69. Jin Y, Kanna S, Wu M, et al. 2007. Toxicity of luminescent silica nanoparticles to living cells. Chem Res Toxicol, 20:1126-33.
70. Kawano T, Yamagata M, Takahishi H, et al. 2006. Stabilizing of plasmid DNA in vivo by PEG-modified cationic gold nanoparticles and the gene expression assisted with electrical pulses. J Control Release, 111:382-9.
71. Khandoga A, Stampfl A, Takenaka S, et al. 2004. Ultrafine particles exert prothrombotic but not inflammatory effects on the hepatic microcirculation in healthy mice in vivo. Circulation, 109:1320-5.
72. Kim SY, Lee YM, Baik DJ, et al. 2003. Toxic characteristics of methoxy poly(ethylene glycol)/poly(-̇caprolactone) nanospheres; in vitro and in vivo studies in the normal mice. Biomaterials, 24:55-63.
73. Kipp JE. 2004. The role of solid nanoparticle technonogy in the parental delivery of poorly water-soluble drugs. Int J Pharm, 284:109-22.
74. Kirchner C, Liedl T, Kudera S, et al. 2005. Cytotoxicity of colloidal CdSe and CdSe/ZnS nanoparticles. Nano Letters, 5:331-8.
75. Konan YN, Chevallier J, Gurny R, et al. 2003. Encapsulation of p-THPP into nanoparticles: cellular uptake, subcellular localization and effect of serum on photodynamic activity. Photochem Photobiol, 77:638-44.
76. Koziara JM, Lockman PR, Allen DD, et al. 2004. Paclitaxel nanoparticles for the potential treatment of brain tumors. J Control Release, 99:259-69.
77. Koziara JM, Lockman PR, Allen DD, et al. 2006. The blood brain barrier and brain drug delivery J Nanosci Nanotechnol, 6:2712-35.
78. Kreuter J. 2001. Nanoparticulate systems for brain delivery of drugs. Adv Drug Deliv Rev, 47:65-81.
79. Kreuter J. 2004. Influence of the surface properties on nanoparticle-mediated transport of drugs to the brian. J Nanosci Nanotechnol, 4:484-8.
80. Kreuter J, Ramge P, Petrov V, et al. 2003. Direct evidence that polysorbate-80-coated poly(butylcyanoacrylate) nanoparticles deliver drugs of the CNS via specific mechanisms requiring prior binding of drug to the nanoparticles. Pharm Res, 20:409-16.
81. Kreyling WG, Semmler M, Möller W. 2004. Dosimetry and toxicology of ultrafine particles. J Aerosol Med, 17:140-52.
82. Kreyling WG, Semmler M, Erbe F, et al. 2002. Translocation of ultrafine insoluble iridium particles from lung epithelium to extrapulmonary organs is size dependent but very low. J Toxicol Environ Health Part A, 65:1513-30.
83. Lai M-K, Chang C-Y, Lien Y-W, et al. 2006. Application of gold nanoparticles to microencapsulation of thioridazine. J Control Release, 111:352-61.
84. Lam C-W, James JT, McCluskey R, et al. 2004. Pulmonary toxicity of single-wall carbon nanotubes in mice 7 and 90 days after intratracheal instillation. Tox Sc, 77:126-34.
85. La Van DA, McGuire T, Langer R. 2003. Small scale systems for in vivo drug delivery. Nat Biotechnol, 21:1184-91.
86. Lenaerts V, Nagelkerke JF, Van Berkel TJ, et al. 1984. In vivo uptake of polyisobutyl cyanoacrylate nanoparticles by rat liver Kupffer, endothelial, and parenchymal cells. J Pharm Sci. 73:980-2.
87. Lin W, Huang YW, Zhou XD, et al. 2006. In vitro toxicity of silica nanoparticles in human lung cancer cells. Toxicol Appl Pharmacol, 217:252-9.
88. Lockman PR, Koziara JM, Mumper RJ, et al. 2004. Nanoparticle surface charges alter blood-brain barrier integrity and permeability. J Drug Target, 12:635-41.
89. Lockman PR, Koziara JM, Roder KE, et al. 2003. In vivo and in vitro assessment of baseline blood-brain-barrier parameters in the presence of novel nanoparticles. Pharm Res, 20:705-13.
90. Loo C, Lin A, Hirsch L, et al. 2004. Nanoshell-enabled photonics-based imaging and therapy of cancer. Technol Cancer Res Treat, 3:33-40.
91. Lovern SB, Klaper R. 2006. Daphnia magna mortality when exposed to titanium dioxide and fullerene (C60) nanoparticles. Environ Toxicol Chem, 25:1132-7.
92. Lovric J, Bazzi HS, Cuie Y, et al. 2005. Differences in subcellular distribution and toxicity of green and red emitting CdTe quantum dots. J Mol Med, 83:377-85.
93. Lovric J, Cho SJ, Winnik FM, et al. 2005. Unmodified cadmium telluride quantum dots induce reactive oxygen species formation leading to multiple organelle damage and cell death. Chem Biol, 12:1159-61.
94. Lowery AR, Gobin AM, Day Es, et al. 2006. Immunonanoshells for targeted photothermal ablation of tumor cells. Int J Nanomedicine, 1:149-54.
95. Metselaar JM, Storm G. 2005. Liposomes in the treatment of inflammatory disorders. Expert Opin Drug Deliv, 2:465-76.
96. Michaelis K, Hoffmann MM, Dreis S, et al. 2006. Covalent linkage of apolipoprotein E to albumin naniparticles strongly enhances drug transport into the brain. J Pharmacol Exp Ther, 317:1246-53.
97. Minko T, Pakunlu RI, Wang Y, et al. 2006. New generation of liposomal drugs for cancer. Anticancer Agents Med Chem, 6:537-52.
98. Mills NL, Tornqvist H, Robinson SD, et al. 2005. Diesel exhaust inhalation causes vascular dysfunction and impaired endogenous fibrinolysis. Circulation, 112:3930-36.
99. Moghimi SM, Hunter AC, Murray JC. 2001. Long-circulating and target specific nanoparticles: theory and practice. Pharmacol Rev, 53:283-318.
100. Monteiro-Riviere NA, Nemanich RJ, Inman AO, et al. 2005. Multi-walled carbon nanotube interactions with human epidermal keratinocytes. Toxicol Lett, 155:377-84.
101. Muller J, Huaux F, Moreau N, et al. 2005. Respiratory toxicity of multi-wall carbon nanotubes. Toxicol Appl Pharmacol, 207:221-31.
102. Muller RH, Mader K, Gohla S. 2000. Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur J Pharm Biopharm, 50:161-77.
103. Na K, Lee KH, Lee DH, et al. 2006. Biodegradable thermo-sensitive nanoparticles from poly(L-lactic acid)/poly(ethylene glycol) alternating multiblock copolymer for potential anti-cancer drug carrier. Eur J Pharm Sci, 27:115-22.
104. Nel A, Xia T, Madler L, et al. 2006. Toxic potential of materials at the nanolevel. Science, 311:622-7.
105. Nemmar A, Hoet PH, Vanquickenborne B, et al. 2002. Passage of inhaled particles into the blood circulation in humans. Circulation, 105:411-14.
106. Nemmar A, Hoylaerts MF, Hoet PH, et al. 2003. Size effect of intraytracheally instilled particles on pulmonary inflammation and vascular thrombosis. Toxicol Appl Pharmacol, 186:38-45.
107. Niidome T, Yamagata M, Okamoto Y, et al. 2006. PEG-modified gold nanorods with a stealth character for in vivo applications. J Control Release, 114:343-7.
108. Nobs L, Buchegger F, Gurny R, et al. 2004. Poly(lactic acid) nanoparticles labeled with biologically active Neutravidin™ for active targeting. Eur J Pharm Biopharm, 58:483-90.
109. Oberdörster E. 2004. Manufactured nanomaterials (fullerenes, C60) induce oxidative stress in the brain of juvenile largemouth bass. Environ Health Perspect, 112:1058-62.
110. Oberdörster G. 1996. Significance of particle parameters in the evaluation of exposure-dose-response relationships of inhaled particles. Inhal Toxicol, 8(Suppl):73-89.
111. Oberdörster G, Maynard A, Donaldson K, et al. 2005. Principles for characterizing the potential human health effects from exposure to nanomaterials: elements of a screening strategy. Part Fibre Toxicol, 2, 8.
112. Oberdörster G, Oberdörster E, Oberdörster J. 2005. Nanotoxicology: An emerging discipline evolving from studies of ultrafine particles. Environ Health Perspect, 113:823-39.
113. Oberdörster G, Sharp Z, Atudorei V, et al. 2004. Translocation of inhaled ultrafine particles to the brain. Inhalation Toxicol, 16:437-45.
114. Olivier JC, Fenart L, Chauvet R, et al. 1999. Indirect evidence that drug brain targeting using polysorbate 80-coated polybutylcyanoacrylate nanoparticles is related to toxicity. Pharm Res, 16:1836-42
115. O'Neal DP, Hirsch LR, Halas NJ, et al. 2004. Photo-thermal tumor ablation in mice using near infrared-absorbing nanoparticles. Cancer Lett, 209:171-6.
116. Paciotti GF, Meyer L, Weinreich D, et al. 2004. Colloidal gold: a novel nanoparticle vector for tumor directed drug delivery. Drug Deliv, 11:169-83.
117. Panyam J, Zhou WZ, Prabha S, et al. 2002. Rapid endo-lysosomal escape of poly(DL-lactide-co-glycolide) nanoparticles: implications for drug and gene delivery. FASEB J, 16:1217-26.
118. Pardridge WM. 2007. Blood-brain barrier delivery. Drug Discovery Today, 12:54-61.
119. Peracchia MT, Fattal E, Desmaele D, et al. 1999. Stealth PEGylated polycyanoacrylate nanoparticles for intravenous administration and splenic targeting. J Control Release, 60:121-8.
120. Pope CA, Burnett RT, Thurston GD, et al. 2004. Cardiovascular mortality and long term exposure to particulate air pollution: epidemiological evidence of genearal pathophysiological pathways of disease. Circulation, 109:71-7.
121. Prinzen L, Miserus R-JJHM, Dirksen A, et al. 2007. Optical and magnetic resonance imaging of cell death and platelet activation using annexin A5-functionalized quantum dots. Nano Lett, 7:93-100.
122. Radomski A, Jurasz P, Alonso-Escolano D, et al. 2005. Nanoparticle-induced platelet aggregation and vascular thrombosis. Br J Pharmacol, 146:882-93.
123. Radt B, Smith TA, Caruso F. 2004. Optically addressable nanostructured capsules. Adv Mater, 16:2184-9.
124. Ravi Kumar MN, Gameti M, Mohapatra SS, et al. 2004. Cationic silica nanoparticles as gene carriers: synthesis, characterization and transfection efficiency in vitro and in vivo. J Nanosci Nanotechnol, 4:876-81.
125. Renn O, Roco MC. 2006. Nanotechnology and the need for risk governance. J Nanoparticle Research, 8:153-91.
126. Ricci-Junior E, Marchetti JM. 2006. Preparation, characterization, photocytotoxicity assay of PLGA nanoparticles containing zinc(II)phthalocyanine for photodynamic therapy use. J Microencapsul, 23:523-38.
127. Saez A, Guzman M, Molpeceres J, et al. 2000. Freeze-drying of polycaprolactone and poly(D,L-lactic-glycolic) nanoparticles induce minor particle size changes affecting the oral pharmacokinetics of loaded drugs. Eur J Pharm Biopharm, 50:379-87.
128. Sayes CM, Gobin AM, Ausman KD, et al. 2005. Nano-C60 cytotoxicity is due to lipid peroxidation. Biomaterials, 26:7587-95.
129. Sayes CM, Liang F, Hudson JL, et al. 2006. Functionalization density dependence of single-walled carbon nanotubes cytotoxicity in vitro. Toxicol Lett, 161:135-42.
130. [SCENIHR] EU Scientific Committee on Emerging and Newly Identified Health Risks. 2006. Modified Opinion (after public consultation) on the appropriateness of existing methodologies to assess the potential risks associated with engineered and adventitious products of nanotechnologies. SCENIHR/002/05. Accessed 23 June 2006. URL: http://ec.europa.eu/health/ph_risk/committees/04_scenihr/docs/ scenihr_o_003b.pdf
131. Schins RP, Duffin R, Hohr D, et al. 2002. Surface modification of quartz inhibits toxicity, particle uptake, and oxidative DNA damage in human lung epithelial cells. Chem Res Toxicol, 15:1166-73.
132. Schins RPF, Lightbody JH, Borm PJA, et al. 2004. Inflammatory effects of coarse and fine particulate matter in relation to chemical and biological constituents. Toxicol Appl Pharmacol, 195:1-11.
133. Seki J, Sonoke S, Saheki A, et al. 2004. A nanometer lipid emulsion, lipid nano-sphere (LNS), as a parenteral drug carrier for passive drug targeting. Int J Pharm, 273:75-83.
134. Senior J, Crawley JCW, Fisher D, et al. 1985. Influence of surface hydrophobicity of liposomes on their interaction with plasma protein and clearance from the circulation: studies with poly(ethylene glycol)-coated vesicles. Biochim Biophys Acta, 1062:77-82.
135. Senior J, Gregoriadis G. 1982. Is half-life of circulating small unilamellar liposomes determined by changes in their permeability? FFBS Lett, 145:109-14.
136. Shenoy D, Fu W, Li J et al. 2006. Surface functionalization of gold nanoparticles using hetero-bifunctional poly(ethylene glycol) spacer for intracellular tracking and delivery. Int J Nanomedicine, 1:51-7.
137. Shim J, Seok Kang H, Park WS, et al. 2004. Transdermal delivery of minoxidil with block copolymer nanoparticles. J Control Release, 97:477-84.
138. Shiohara A, Hoshino A, Hanaki K, et al. 2004. On the cytotoxicity of quantum dots. Microbiol Immunol, 48:669-75.
139. Shvedova AA, Castranova V, Kisin ER, et al. 2003. Exposure to carbon nanotube material: assessment of nanotube cytotoxicity using human keratinocyte cells. J Toxicol Environm Health Part A, 66:1909-26.
140. Stern JM, Stanfield J, Lotan Y, et al. 2007. Efficacy of laser-activated gold nanoshells in ablating prostate cancer cells in vitro. J Endourol 21:939-43.
141. Su C-H, Sheu H-S, Lin C-Y, et al. 2006. Nanoshell resonance imaging contrast agents. J Am Chem Soc. 129:2139-46.
142. Suwa T, Hogg JC, Quinlan KB, et al. 2002. Particulate air pollution induces progression of atherosclerosis. Am Coll Cardiol, 39:943-5.
143. Svenson S, Tomalia DA. 2005. Dendrimers in biomedical applications - reflections on the field. Adv Drug Del Rev, 57:2106-29.
144. Takenaka S, Karge E, Kreyling WG, et al. 2006. Distribution pattern of inhaled ultrafine gold nanoparticles in the rat lung. Inhalation Toxicol, 18:733-40.
145. The Royal Society and The Royal Academy of Engineering. 2004. Nanoscience and nanotechnologies: opportunities and uncertainties. London, UK. Accessed 10 August 2004. URL: http://www.nanotec.org.uk/ finalReport.htm
146. Tiwari SB, Amiji MM. 2006. A review of nanocarrier-based CNS delivery systems. Current Drug Delivery, 3:219-32.
147. Tomazic-Jezic VJ, Merritt K, Umbreit TH. 2001. Significance of the type an dsize of biomaterial particles on phagocytosis and tissue distribution. J Biomed Mater Res, 55:523-9.
148. Warheit DB, Laurence BR, Reed KL, et al. 2004. Comparative pulmonary toxicity assessment of single-wall carbon nanotubes in rats. Toxicol Sci, 77:117-25.
149. Weissenbock A, Wirth M, Gabor F. 2004. WGA grafted PLGA-nanospheres: preparation and association with Caco-2 cells. J Contr Release, 99:383-92.
150. Win KY, Feng SS. 2006. In vitro and in vivo studies on vitamin E TPGS-emulsified poly(D,L-lactic-co-glycolic acid) nanoparticles for paclitaxel formulation. Biomateriais, 27:2285-91.
151. Wissing SA, Kayser O, Müller RH. 2004. Solid lipid nanoparticles for parental drug delivery. Adv Drug Deliv Rev, 56:1257-72.
152. Xia T, Kovochich M, Brant J, et al. 2006. Comparison of ambient and manufactured nanoparticles to induce cellular toxicity according to an oxidative stress paradigm. Nano Lett, 6:1794-807.
153. 2. J Am Chem Soc, 125:12803-9.
154. Zhang L, Hu Y, Jiang X, et al. 2004.. Camptothecin derivative-loaded poly(caprolactone-co-lactide)-b-PEG-b-poly(caprolactone-co-lactide) nanoparticles and their biodistribution in mice. J Control Release, 96:135-48.
155. Zhu S, Oberdörster E, Haasch ML. 2006. Toxicity of an engineered nanoparticle (fullerene, C60) in to aquatic species, Daphnia and flathead minnow. Mar Environ Res, 62(Suppl):S5-9.